수의 진단 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the veterinary diagnostics market size was valued at USD 8.73 billion in 2025 and is estimated to grow from USD 9.53 billion in 2026 to reach USD 15.05 billion by 2031, at a CAGR of 9.57% during the forecast period (2026-2031).

This report is Segmented by Product Type (Instruments, and More), Technology (Immunodiagnostics, Clinical Biochemistry, and More), Animal Type (Companion Animals and Livestock Animals), End-User (Veterinary Hospitals & Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Veterinary Diagnostics Market Trends and Insights

Rising Companion Animal Ownership and Healthcare Spending

Urban Chinese pet owners doubled their annual veterinary spending to CNY 8,200 (USD 1,150) between 2020 and 2025, as the number of single-person households increased. Millennials and Generation Z owners now demand laboratory blood work, thyroid panels, and urinalyses during routine wellness exams, keeping in-clinic chemistry analyzers running near capacity. Enhanced pet-insurance penetration, particularly in North America and Scandinavia, removes cost barriers for advanced imaging and molecular testing. Together, these factors secure a growing baseline for the veterinary diagnostics market.

Growing Prevalence of Zoonotic and Foodborne Diseases

African swine fever outbreaks in Southeast Asia and Eastern Europe triggered compulsory PCR screening for live-pig transport, beginning in 2024, which drove the adoption of rugged, portable analyzers on farms. India's National Animal Disease Control Programme now covers 600 million bovines, requiring quarterly serological assays for brucellosis and FMD. In 2025, H5N1 detections across 16 U.S. states prompted emergency authorizations for 15-minute antigen tests that help isolate infected herds before viral shedding contaminates food supplies. Heightened surveillance budgets are shielding the veterinary diagnostics market from macroeconomic slowdowns.

High Cost of Advanced Diagnostic Instruments and Tests

Five-part-differential hematology analyzers list between USD 25,000 and USD 45,000, while reagents add USD 8,000-12,000 annually - out of reach for clinics where a visit averages USD 30. Only 18% of Kenyan practices owned automated chemistry systems in 2025, resulting in a reliance on manual assays and 3- to 5-day result times. Molecular panels for vector-borne diseases run USD 80-120 per test in the United States, and uninsured clients frequently opt for empirical therapy instead, undermining stewardship goals. Subscription bundles and reagent-rental schemes are emerging but remain concentrated in high-volume clinics able to amortize equipment costs.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advancements in Point-of-Care and Molecular Diagnostics
2. Government Surveillance Programs Mandating Livestock Screening
3. Shortage of Skilled Veterinary Diagnostic Professionals

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Kits and reagents generated 46.54% of 2025 revenue, reinforcing a consumable-driven model that secures continuous cash flow for vendors; in contrast, software and services are on track to grow at 11.45% annually, signaling a strategic pivot toward analytics subscriptions within the veterinary diagnostics market. Instruments, although a smaller slice, now feature modular add-on panels such as coagulation or electrolyte modules - that extend their useful life without requiring full replacement.

Cloud-native laboratory information platforms aggregate multi-clinic data, standardize quality control, and enable benchmarking across corporate hospital chains. Zoetis' Vetscan Cloud and Heska's bundled reagent-maintenance-AI packages convert capital expenditure into operating expenses, a draw for consolidators seeking predictable margins. This services-led evolution positions vendors to capture a higher share of the veterinary diagnostics market over the forecast window.

Immunodiagnostics accounted for 38.64% of the revenue in 2025, while molecular diagnostics are expected to post an 11.32% CAGR, leveraging declining reagent prices and sample-to-answer automation that eliminates the need for specialized technicians. Classic biochemistry and hematology platforms remain entrenched, although micro-sample capabilities now reduce the required volumes from 1 mL to mere microliters, easing constraints in feline and exotic-pet testing.

IDEXX's RealPCR has earned USDA approval for non-invasive screening of porcine reproductive and respiratory syndrome (PRRS) via oral fluids, illustrating how molecular workflows are moving from reference labs into barns and exam rooms. Thermo Fisher's 12-month-stable lyophilized PCR reagents further democratize access in regions with unreliable cold chains. These advances underpin sustained momentum for the veterinary diagnostics market.

Complete Report Scope:

• By Product Type
  • Instruments
  • Kits And Reagents
  • Software And Services
• By Technology
  • Immunodiagnostics
  • Clinical Biochemistry
  • Molecular Diagnostics
  • Hematology
  • Other Technologies
• By Animal Type
  • Companion Animals
    • Dogs
    • Cats
    • Other Companion Animals
  • Livestock Animals
    • Cattle
    • Swine
    • Poultry
    • Other Livestock Animals
• By End-User
  • Veterinary Hospitals & Clinics
  • Reference Laboratories
  • Ambulatory & Mobile Vet Services
  • Research Institutes & Universities
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America accounted for 41.45% of the veterinary diagnostics market revenue in 2025, with the U.S. spending USD 4.2 billion, driven by corporate chains standardizing protocols and leveraging bulk-buy reagent contracts. Canada's federal subsidies for bovine tuberculosis and chronic wasting disease surveillance further buoy laboratory demand. Strict FDA and Health Canada validation pathways do elongate the time-to-market, but they justify premium pricing once approvals are obtained.

The Asia-Pacific region is projected to be the fastest-growing region, with a 10.54% CAGR through 2031. China's 120 million-strong pet population already mirrors Western per-pet spending in Tier-1 cities, while India's mobile labs and new district diagnostic centers are closing testing gaps in pastoral belts. Japan's aging pets create demand for chronic-disease panels, and South Korea's 12% pet-insurance penetration eases the adoption of high-ticket imaging.

Europe enjoys stable growth, underpinned by high pet insurance take-up and EU-mandated livestock tracking. Germany subsidizes PCR testing for African swine fever in wild boar carcasses, while Spain and France ramp up avian-influenza monitoring ahead of export seasons. The Middle East and Africa register smaller revenues today. Still, they are expected to accelerate as Gulf states invest in food security and African nations receive WOAH-FAO aid for outbreak control. South America, led by Brazil's poultry and swine integrators, installs on-site PCR labs to meet export-buyer pathogen-free certifications.

1. Abaxis
2. Biochek
3. bioMerieux
4. BioNote Inc.
5. Bio-Rad Laboratories
6. Boehringer Ingelheim
7. Covetrus
8. Danaher
9. Esaote
10. Heska
11. IDEXX
12. IDVet
13. Indical Bioscience
14. Mindray
15. Neogen
16. QIAGEN
17. Randox Laboratories
18. Thermo Fisher Scientific
19. Virbac
20. Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope Of The Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Companion Animal Ownership and Healthcare Spending
  • 4.2.2 Growing Prevalence of Zoonotic and Foodborne Diseases
  • 4.2.3 Technological Advancements in Point-of-Care and Molecular Diagnostics
  • 4.2.4 Expansion of Pet Insurance Coverage and Veterinary Expenditure
  • 4.2.5 Integration of Artificial Intelligence for Automated Image and Data Analysis
  • 4.2.6 Government Surveillance Programs Mandating Livestock Disease Screening
• 4.3 Market Restraints
  • 4.3.1 High Cost of Advanced Diagnostic Instruments and Tests
  • 4.3.2 Shortage of Skilled Veterinary Diagnostic Professionals
  • 4.3.3 Limited Data Interoperability Slowing Adoption of Connected Diagnostic Platforms
  • 4.3.4 Import Tariffs and Supply Chain Disruptions Affecting Consumable Availability
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat Of New Entrants
  • 4.7.2 Bargaining Power Of Buyers
  • 4.7.3 Bargaining Power Of Suppliers
  • 4.7.4 Threat Of Substitute Products
  • 4.7.5 Intensity Of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Instruments
  • 5.1.2 Kits And Reagents
  • 5.1.3 Software And Services
• 5.2 By Technology
  • 5.2.1 Immunodiagnostics
  • 5.2.2 Clinical Biochemistry
  • 5.2.3 Molecular Diagnostics
  • 5.2.4 Hematology
  • 5.2.5 Other Technologies
• 5.3 By Animal Type
  • 5.3.1 Companion Animals
    • 5.3.1.1 Dogs
    • 5.3.1.2 Cats
    • 5.3.1.3 Other Companion Animals
  • 5.3.2 Livestock Animals
    • 5.3.2.1 Cattle
    • 5.3.2.2 Swine
    • 5.3.2.3 Poultry
    • 5.3.2.4 Other Livestock Animals
• 5.4 By End-User
  • 5.4.1 Veterinary Hospitals & Clinics
  • 5.4.2 Reference Laboratories
  • 5.4.3 Ambulatory & Mobile Vet Services
  • 5.4.4 Research Institutes & Universities
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest Of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest Of Asia-Pacific
  • 5.5.4 Middle East And Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest Of Middle East And Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest Of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)}
  • 6.3.1 Abaxis
  • 6.3.2 BioChek BV
  • 6.3.3 BioMerieux SA
  • 6.3.4 BioNote Inc.
  • 6.3.5 Bio-Rad Laboratories Inc.
  • 6.3.6 Boehringer Ingelheim GmbH
  • 6.3.7 Covetrus Inc.
  • 6.3.8 Danaher Corporation
  • 6.3.9 Esaote SpA
  • 6.3.10 Heska Corporation
  • 6.3.11 IDEXX Laboratories Inc.
  • 6.3.12 IDVet
  • 6.3.13 INDICAL Bioscience GmbH
  • 6.3.14 Mindray Medical International Ltd.
  • 6.3.15 Neogen Corporation
  • 6.3.16 QIAGEN N.V.
  • 6.3.17 Randox Laboratories Ltd.
  • 6.3.18 Thermo Fisher Scientific Inc.
  • 6.3.19 Virbac SA
  • 6.3.20 Zoetis Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment